Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.32 |
| ▸ | RIPK1 | Q13546 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22096277 | 0.92 | AXL (0.30) | — | |
| SCHEMBL22739004 | 0.87 | — | — | |
| SCHEMBL29566128 | 0.82 | TMPRSS2 (0.32) | TMPRSS2RIPK1 | |
| SCHEMBL23047656 | 0.82 | CSNK2A2 (0.33) | RIPK1 | |
| SCHEMBL25012545 | 0.82 | BTN3A1 (0.33) | RIPK1 | |
| SCHEMBL24149678 | 0.82 | DOT1L (0.31) | — | |
| SCHEMBL10154374 | 0.82 | TMPRSS2 (0.33) | TMPRSS2RIPK1 | |
| SCHEMBL24148708 | 0.81 | CYP3A4 (0.32) | RIPK1 | |
| SCHEMBL18636608 | 0.81 | CYP3A4 (0.32) | RIPK1 | |
| SCHEMBL25012565 | 0.81 | BTN3A1 (0.34) | RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11773126-B2 | Substituted nucleosides, nucleotides and analogs thereof | Janssen Pharmaceuticals, Inc. (US) | 2023-10-03 | — | — | US | disclosed |
| US-20210395288-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALAOGS THEREOF | JANSSSEN BIOPHARMA, INC. (US) | 2021-12-23 | — | — | US | disclosed |
| US-11149049-B2 | Substituted nucleosides, nucleotides and analogs thereof | Janssen Biopharma, Inc. (US) | 2021-10-19 | — | — | US | disclosed |
| US-20200277321-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALAOGS THEREOF | Janssen Pharmaceuticals, Inc. | 2020-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200277321-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALAOGS THEREOF | PNP, RNGTT, NT5C3B | TMPRSS2 664/4885RIPK1 3903/4885 |
| US-11773126-B2 | Substituted nucleosides, nucleotides and analogs thereof | PNP, TYMP, SLC29A1 | TMPRSS2 867/4885RIPK1 4107/4885 |
| US-20210395288-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALAOGS THEREOF | PNP, RNGTT, NT5C3B | TMPRSS2 664/4885RIPK1 3903/4885 |
| US-11149049-B2 | Substituted nucleosides, nucleotides and analogs thereof | PNP, TYMP, SLC29A1 | TMPRSS2 867/4885RIPK1 4107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.